Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent clade B virus-like particle vaccine

AIDS Research and Human Retroviruses

Volumn 28, Issue 9, 2012, Pages 863-872

  McBurney, Sean P ^a,b   Landucci, Gary ^c   Forthal, Donald N ^c   Ross, Ted M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSENSUS CLADE B VIRUS LIKE PARTICLE VACCINE; GAG PROTEIN; POLYVALENT CLADE B VIRUS LIKE PARTICLE VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNOGENICITY; INFECTION RATE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS ENVELOPE; VIRUS LOAD;

EID: 84865462039     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0351     Document Type: Article

References (56)

1. UNAIDS. 2009 UNAIDS Annual Report. In: Joint United Nations programme on HIV/AIDS, 2010.
2. Robertson DL, Anderson JP, Bradac JA, et al. A reference guide to HIV-1 classification. In: Human Retroviruses and AIDS: A Compilation and Analysis of Nucleic and Amino Acid Sequences (Kuiken CL, Foley B, Hanh BB, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2000, pp. 492-505.
3. Barnett SWa, Srivastava IKa, Kan Ea, Zhou Fa, Goodsell Aa, Cristillo ADb, et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008;22:339-348.
4. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990;345:622-625.
5. Bogers WMJM, Davis D, Baak I, Kan E, Hofman S, Sun Y, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008;382:217-225.
6. Cho MW, Kim YB, Lee MK, Gupta KC, Ross W, Plishka R, et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J Virol 2001;75:2224-2234. (Pubitemid 32147561)
7. Polacino P, Stallard V, Klaniecki JE, Montefiori DC, Langlois AJ, Richardson BA, et al. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol 1999;73:618-630. (Pubitemid 28565406)
8. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473:523-527.
9. McBurney SP and Ross TM: Viral sequence diversity: Challenges for AIDS vaccine designs. Expert Rev Vaccines 2008;7:1405-1417.
10. Slobod K, Coleclough C, Bonsignori M, Brown SA, Zhan X, Surman S, Zirkel A, et al. HIV vaccine rationale, design and testing. Current HIV Res 2005;3:107-112. (Pubitemid 40614117)
11. Chakrabarti BK, Ling X, Yang Z-Y, Montefiori DC, Panet A, Kong W-P, et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 2005;23:3434.
12. Kong W-P, Huang Y, Yang Z-Y, Chakrabarti BK, Moodie Z, and Nabel GJ: Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 2003;77:12764-12772. (Pubitemid 37430671)
13. Lemiale F, Brand D, Lebigot S, Verrier B, Buzelay L, Brunet S, and Barin F: Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: A comparative study using multivalent vaccine approaches. JAIDS J Acquir Immune Defic Syndr 2001;26(5):413-422. (Pubitemid 32489019)
14. Ljungberg K, Rollman E, Eriksson L, Hinkula J, and Wahren B: Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002;302:44.
15. McBurney SP and Ross TM: Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 2009;27:4337-4349.
16. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, et al. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 2005;34:226-236. (Pubitemid 41179584)
17. Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006;348:341-353.
18. Rollman E, Hinkula J, Arteaga J, Zuber B, Kjerrstrom A, Liu M, et al. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther 2004; 11:1146-1154. (Pubitemid 39117310)
19. Seaman MS, Xu L, Beaudry K, Martin KL, Beddall MH, Miura A, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005;79: 2956-2963. (Pubitemid 40270574)
20. Slobod KS, Lockey TD, Howlett N, Srinivas RV, Rencher SD, Freiden PJ, et al. Subcutaneous administration of a recombinant vaccinia virus vaccine expressing multiple envelopes of HIV-1. Eur J Clin Microbiol Infect Dis 2004;23:106.
21. Doria-Rose NA, Learn GH, Rodrigo AG, Nickle DC, Li F, Mahalanabis M, et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 2005;79: 11214-11224. (Pubitemid 41170663)
22. Gao F, Weaver EA, Lu Z, Li Y, Liao H-X, Ma B, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005;79:1154-1163. (Pubitemid 40053898)
23. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 2007;360:218-234.
24. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006;352:438-449. (Pubitemid 44216009)
25. Liao H-X, Sutherland LL, Xia S-M, Brock ME, Scearce RM, Vanleeuwen S, et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006;353: 268-282. (Pubitemid 44404137)
26. Scriba TJ, zur Megede J, Glashoff RH, Treurnicht FK, Barnett SW, and van Rensburg EJ: Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. Vaccine 2005;23:1158.
27. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao H-X, Ma B-J, et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group M consensus Env immunogen. J Virol 2006;80:6745-6756. (Pubitemid 44025174)
28. Simon V, Ho DD, and Abdool Karim Q: HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006;368:489-504. (Pubitemid 44142771)
29. Green TD, Montefiori DC, and Ross TM: Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 2003; 77:2046-2055. (Pubitemid 36110017)
30. Young KR, Smith JM, and Ross TM: Characterization of a DNA vaccine expressing a human immunodeficiency viruslike particle. Virology 2004;327:262-272. (Pubitemid 39209331)
31. Lowe DM, Parmar V, Kemp SD, and Larder BA: Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase. FEBS Lett 1991;282:231-234.
32. Mizuno A, Ido E, Goto T, Kuwata T, Nakai M, and Hayami M: Mutational analysis of two zinc finger motifs in HIV type 1 nucleocapsid proteins: Effects on proteolytic processing of Gag precursors and particle formation. AIDS Res Hum Retroviruses 1996;12:793-800. (Pubitemid 26171120)
33. Chao SF, Chan VL, Juranka P, Kaplan AH, Swanstrom R, and Hutchison CA, 3rd: Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 1995;23:803-810.
34. Le Grice SF, Naas T, Wohlgensinger B, and Schatz O: Subunit- selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J 1991;10:3905-3911. (Pubitemid 21905419)
35. Tilney NL: Patterns of lymphatic drainage in the adult laboratory rat. J Anat 1971;109:369-383.
36. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005;79:10108-10125. (Pubitemid 41098552)
37. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, et al. Genetic and neutralization properties of subtype c human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa J Virol 2006;80:11776-11790. (Pubitemid 44788890)
38. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, and Klinman DM: CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 2002;168:1659-1663. (Pubitemid 34135761)
39. Montefiori DC: Evaluating neutralizing antibodies against HIV, SIV and SHIV in a luciferase reporter gene assay. In: Current Protocols in Immunology (Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, and Coico R, eds.). John Wiley & Sons, New York, 2004.
40. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005;79:10108-10125. (Pubitemid 41098552)
41. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles Jeremiah G, et al. Antibody Dependent Cellular Cytotoxicity Independently Predicts Survival in Severely Immunocompromised Human Immunodeficiency Virus Infected Patients. The Journal of Infectious Diseases 1999;180:1338-1341. (Pubitemid 30070224)
42. Fernández-García A, Cuevas MT, Muñoz-Nieto M, Ocampo A, Pinilla M, García V, et al. Development of a panel of wellcharacterized human immunodeficiency virus type 1 isolates from newly diagnosed patients including acute and recent infections. AIDS Res Hum Retroviruses 2009;25:93-102.
43. Harouse JM, Gettie A, Tan RCH, Blanchard J, and Cheng-Mayer C: Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999;284:816-819. (Pubitemid 29291349)
44. O'Connor DH, Mothe BR, Weinfurter JT, Fuenger S, Rehrauer WM, Jing P, et al. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol 2003;77:9029-9040. (Pubitemid 36936111)
45. Zhang Z-Q, Fu T-M, Casimiro DR, Davies M-E, Liang X, Schleif WA, et al. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol 2002;76:12845-12854. (Pubitemid 35386968)
46. McBurney SP, Young KR, and Ross TM: Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007;358:334-346. (Pubitemid 46138113)
47. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000;165:5170-5176.
48. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34:269-280.
49. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010;84: 7161-7173.
50. Bomsel M, Tudor D, Drillet A-S, Alfsen A, Ganor Y, Roger M-Gl, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34:269-280.
51. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010;84:7161-7173.
52. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin A-M, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006;80: 6177-6181. (Pubitemid 43849196)
53. Lore K and Larsson M: The role of dendritic cells in the pathogenesis of HIV-1 infection. Apmis 2003;111:776-788. (Pubitemid 37130024)
54. Wilflingseder D, Banki Z, Dierich MP, and Stoiber H: Mechanisms promoting dendritic cell-mediated transmission of HIV. Mol Immunol 2005;42:229-237. (Pubitemid 39361451)
55. Haynes B: Case control study of the RV144 study for immune correlates: The analysis and way forward. AIDS Vaccine 2011 meeting, Bangkok, Thailand, September 12-15, 2011.
56. Montefiori DC, Safrit JT, Lydy SL, Barry AP, Bilska M, Vo HTT, et al. Induction of neutralizing antibodies and Gagspecific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol 2001;75:5879-5890. (Pubitemid 32553118)